Efficacy and safety of pentoxifylline in treatment and recovery of patients with COVID-19

Phase 3

Conditions: COVID-19.
COVID-19, virus identified
U07.1

Registration Number: IRCT20170809035597N2

Lead Sponsor: Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 150

Inclusion Criteria

Admitted patients with COVID-19
Moderate to severe disease
Stable patients
Patients should not have bleeding disorders
Patients do not have a history of heart attack and stroke
Patients without history of ocular or cerebral hemorrhage
No pregnancy or breastfeeding
Patients without history of intolerance to PTX or other xanthines such as caffeine, theophylline and tobromine
Patients without gastric ulcers
Patient without history of porphyria
Patients with no prominent renal or hepatic or cardiac dysfunction
Patients without history of major surgery in the past 2 weeks
Patients without history of cancer
Patients without need to use any therapeutic blood thinners, including aspirin and warfarin

Exclusion Criteria

Allergy to any of the drugs studied, including pentoxifylline
Occurrence of any bleeding during the study (in the stomach, brain, eyes, ...)
Drug intolerance or the occurrence of any severe side effects during treatment, such as gastrointestinal intolerance, does not respond to pre-determined measures of anti-acids... or the occurrence of skin drug reactions to the received treatment protocol and ...
Being pregnant during the study
Occurrence of heart attack and stroke during the study
Drop in pressure below 10 mm Hg or instability of the patient's vital signs
Require intubation during study or hospitalization in the ICU
Increase in the severity of COVID-19 disease during the study so that the need for hospitalization in the ICU or the need to change the treatment protocol
The use of a therapeutic drug other than the standard drug in this study